Alkermes Plc (NASDAQ:ALKS) CAO Iain Michael Brown sold 10,652 shares of the firm’s stock in a transaction on Saturday, December 29th. The stock was sold at an average price of $54.81, for a total transaction of $583,836.12. Following the completion of the sale, the chief accounting officer now owns 16,943 shares of the company’s stock, valued at approximately $928,645.83. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Iain Michael Brown also recently made the following trade(s):
- On Friday, December 29th, Iain Michael Brown sold 10,652 shares of Alkermes stock. The shares were sold at an average price of $54.81, for a total transaction of $583,836.12.
Shares of Alkermes Plc (NASDAQ:ALKS) opened at $58.97 on Friday. The stock has a market cap of $9,070.00, a price-to-earnings ratio of -53.13 and a beta of 2.13. The company has a quick ratio of 2.72, a current ratio of 3.05 and a debt-to-equity ratio of 0.23. Alkermes Plc has a twelve month low of $46.42 and a twelve month high of $63.40.
Alkermes (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.04. Alkermes had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. During the same quarter in the previous year, the firm earned ($0.09) earnings per share. The firm’s revenue for the quarter was up 20.6% compared to the same quarter last year. equities analysts predict that Alkermes Plc will post -0.59 EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in ALKS. Toronto Dominion Bank grew its position in Alkermes by 12.7% in the 2nd quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock valued at $109,000 after buying an additional 212 shares in the last quarter. Quantbot Technologies LP bought a new position in Alkermes in the 3rd quarter valued at about $126,000. Virtu Financial LLC bought a new position in Alkermes in the 3rd quarter valued at about $201,000. Dynamic Technology Lab Private Ltd acquired a new stake in Alkermes in the 3rd quarter valued at about $214,000. Finally, Trexquant Investment LP acquired a new stake in Alkermes in the 3rd quarter valued at about $218,000. Institutional investors and hedge funds own 99.17% of the company’s stock.
A number of brokerages have issued reports on ALKS. Barclays cut shares of Alkermes from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 price target on shares of Alkermes and gave the stock a “buy” rating in a report on Friday, October 27th. ValuEngine upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a report on Friday, December 1st. BidaskClub upgraded shares of Alkermes from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Finally, Citigroup set a $62.00 target price on shares of Alkermes and gave the company a “hold” rating in a report on Thursday, October 26th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $63.33.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://ledgergazette.com/2018/01/12/insider-selling-alkermes-plc-alks-cao-sells-583836-12-in-stock.html.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.